{
  "id": 9597265,
  "title": "IN8bio at Sidoti Small-Cap Virtual Conference: gamma-delta push",
  "url": "https://urgent.news/2026/09/24/in8bio-at-sidoti-small-cap-virtual-conference-gamma-delta-push",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-24T17:47:19.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/in8bio-at-sidoti-smallcap-virtual-conference-gammadelta-push-93CH-4915982"
  },
  "original_language": "en",
  "account": null,
  "summary": "IN8bio, a biotech company focused on developing therapies based on gamma-delta T cells, recently addressed a two-pronged strategy at the Sidoti Small-Cap Virtual Conference. The company aims to leverage these unique immune cells for treating autoimmune diseases and glioblastoma. IN8bio highlighted promising early data from its lead autoimmune program, INB-619, which demonstrated strong in vitro B-cell killing with no IL-6 secretion, a marker associated with cytokine release syndrome. In the glioblastoma program, the company reported a median progression-free survival of 13 months, up from 6.6 months, and a median overall survival of 19.5 months, up from 13.2 months. The company raised over $20 million in December 2025 and anticipates a second close of approximately $20 million, which could support operations until the IND submission. IN8bio's CEO, Will, emphasized the company's commitment to developing more precise treatments using gamma-delta T cells, which it believes can act as both direct attackers and coordinators of the immune response.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Definity Financial at CIBC Eastern Institutional Investor Conference: growth push",
        "url": "https://urgent.news/2026/09/24/definity-financial-at-cibc-eastern-institutional-investor-conference",
        "published": "2026-09-24T14:21:06.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}